Search

everythinglearnresearchcommunity

for

Search:↓

The congress concluded that misuse of antifungal drugs in South Asia has led to widespread treatment failure, and new approaches and regional cooperation are needed.

Deleting Gpr54 speeds up hair growth and regeneration.

Topical corticosteroids are the main treatment for Erosive Pustular Dermatosis, but recurrence is common after stopping treatment.

Platelet-rich plasma can increase hair density and may help treat some skin conditions, but it's costly, not FDA-approved, and needs more research.

Accurate early diagnosis of Lichen Planopilaris is crucial to prevent permanent hair loss.

New treatments focusing on immune pathways show promise for stubborn hair loss.

Standardizing light therapy methods could improve spinal cord injury treatment.

New medications could improve treatment for severe alopecia areata in Australia.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.

Advancements in diagnostics, treatments, and technology have improved hair loss detection and restoration, with some types being reversible.

Hair follicles are key to treating vitiligo and alopecia areata, but challenges exist.

Docetaxel often causes hair loss, with limited effective treatments and no cure for permanent hair loss.

3,4,5-tri-O-caffeoylquinic acid promotes hair growth by activating the β-catenin pathway.

Araliadiol may help reduce skin aging and inflammation without killing cells.

A substance called miR-1246 may help treat severe hair loss by reducing certain immune cell activities.

Alopecia areata is hard to treat, but new targeted therapies show promise.

Cyclosporin A helps mice grow hair by blocking a specific protein activity in skin cells.

Cyclosporin A, a drug, reduces TGF-β2 expression in skin cells, potentially causing excessive hair growth through a process involving the calcineurin/NFAT pathway.

Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.

Topical calcineurin inhibitors might be safer than steroids for scarring alopecia, but more research is needed.

Phosphorylation controls TFEB's location in the cell, affecting cell metabolism and stress response.

Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.

Treating psoriasis on the scalp, nails, and skin folds is challenging, often requiring systemic treatments for severe cases, with some success in topical and biologic treatments.

New vitiligo treatments focus on controlling immune damage and restoring skin color.

Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.

European guidelines recommend regular eye and ear exams, skin care, vitamin D supplements, and cautious use of medications for managing congenital ichthyoses.

UV light can help stimulate the growth of new pigment cells from hair follicles in people with vitiligo.

The document concludes that better treatments for CCCA are needed and more research is required to understand its causes related to hairstyling and genetics.

Cutaneous lupus erythematosus is a chronic skin disease that can progress to systemic lupus in some cases and requires treatment to prevent recurrences and scarring.